8th Orphan Drug and Rare Diseases Congress in Boston – Keynote from and panel discussion with Prof. Schönermark

Wed, 2018 / 09 / 05

About the author

Ihr Ansprechpartner Prof. Matthias P. Schönermark, M.D., Ph.D.
Prof. Matthias P. Schönermark, M.D., Ph.D.
Founder and Managing Director
Fon: +49 511 64 68 14 – 0
Fax: +49 511 64 68 14 18
Joins us at the 8th Orphan Drug and Rare Diseases Congress in Boston, MA, USA on the 25th and 26th of September to discuss, how strategies and innovations are driving access and commercialization of orphan drugs.

The major stakeholders of the orphan drug industry will come together at this event. The congress provides a unique platform for all the participants to network with top tier government, hospitals, pharmaceuticals, biopharmaceuticals, non-profit organizations, orphan drugs developers, as well as regional and local manufacturers. The congress is hosted by Paradigm Global Events and we are happy to announce SKC’s involvement.

  • Founder and managing director of SKC, Prof. Matthias P. Schönermark, M.D., Ph. D., will hold a keynote speech at the congress about “Orphan Drugs in Europe – Conquering the largest pharmaceutical market”. The speech will focus on the current situation in Europe from a regulatory and a market access perspective and will highlight key success factors of pricing and reimbursement as well as strategic implications for biopharma companies planning to expand into Europe.

  • You may also have the chance to interact with Prof. Schönermark at the 40 minutes panel discussion “Strategies for Implementing value-based pricing and reimbursement for orphan drugs”. As one of the panelist, Prof. Schönermark will debate about relevant topics such as successful pricing for Rare Diseases, measures designed to limit costs associated with orphan drug reimbursement and incentives to encourage development of orphan rare diseases therapies.


SKC is looking forward to seeing you at the congress.

We are the leading and most reputable strategy consultancy in the German health care sector. Especially orphan drugs with their specific German market access process have been a field of work for us in recent years.

You may also want to attend our free of charge seminars about “Strategic Challenges of Orphan Drug Market Access in Europe” and “Successful Market Access for Gene Therapies – Strategic Solutions”. The seminars are taking place at the Harvard Faculty Club on the day before (24th of September) and we would be delighted to have you as our guest. Please register here (free of charge).

Gain even more insights with our White Paper „Orphan Drugs in German – lessons learned from AMNOG“.

BY Prof. Matthias P. Schönermark, M.D., Ph.D., managing director and Karolin Priese, MBA

Further information are available at:
Paradigm Global Events
to the top